Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLM101 Open-Label Extension in PMM2-CDG
NCT06657859Phase 2Enrolling by invitation
- Sponsor
- Glycomine
- Start
- Sep 2024
- Primary completion
- Sep 2029
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of GLM101 in phosphomannomutase 2 deficiency (PMM2-CDG), sponsored by Glycomine. Primary endpoint: Long-term safety at 4 years. Started Sep 2024; status: enrolling by invitation.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 deficiency (PMM2-CDG)
Beyond the preview
Go deeper on NCT06657859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657859.